Kim McClellan is the current President of the Recurrent Respiratory Papillomatosis Foundation, and she is also a patient with RRP whose life has been radically changed for the better since starting Bevacizumab (Avastin) as a repurposed, off-label treatment. Prior to the start of this treatment, Kim had gone under general anesthesia over 250 times for treatment of her disease.
Through her leadership of the RRPF, recent milestones include leading FDA Listening Sessions, publishing the Bevacizumab Consensus Statement, launching a Pulmonary Tissue Bank at Yale University, and developing a comprehensive Patient Toolkit. RRPF is proud to partner with national and international organizations including Merck, Johns Hopkins, Cincinnati Children’s, Inovio, Precigen, and the National Organization for Rare Disorders (NORD).
RRPF remains committed to amplifying the patient voice and driving collaborative research initiatives to better understand, treat, and ultimately cure RRP without surgical intervention.
